BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles
Yi-Seul Yoon1, Yejin Jang1, Thomas Hoenen2, Heegwon Shin3, Younghoon Lee3, Meehyein Kim1,*
11Innovative Target Research Center, Korea Research Institute of Chemical Technology,
2Institute for Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut,
3Department of Chemistry, Korea Advanced Institute of Science and Technology
Abstract
A chemical library comprising 2,354 drug-like compounds was screened using a transcription and replication-competent virus-like particle (trVLP) system that implements the whole Ebola virus (EBOV) life cycle. Dose-dependent inhibition of Ebola trVLP replication was induced by 15 hit compounds, which target different kinds of G protein-coupled receptors (GPCRs) mainly. Based on the chemical structures, they were divided into three groups, diphenylmethane derivatives, promazine derivatives or without any core skeletons. Within the third group, sertindole, raloxifene, and ibutamoren showed prominent antiviral effects in cells. They down-regulated expression of viral proteins, including the VP40 matrix protein and the envelope glycoprotein, and also reduced the amount of EBOV-derived tetracistronic minigenome RNA incorporated into progeny trVLPs in the culture supernatant. Particularly, ibutamoren, known as an agonist of growth hormone secretagogue receptor (GHSR), showed the most promising antiviral activity with a 50% effective concentration of 0.2 レM, a 50% cytotoxic concentration of 42.4 レM, and a selectivity index of 222.8. Here, we suggest that agonistic molecules to GHSR could be developed as anti-EBOV therapeutics.
Abstract, Accepted Manuscript(in press) [Submitted on July 12, 2019, Accepted on October 16, 2019]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd